EcoDrugPlus

Dna Topoisomerase Ii Beta

Ensembl ID : ENSBMUG00000002127
Gene Symbol: TOP2B
3 Cross references
210 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSBMUG00000025130
Gene Symbol: EML4
3 Cross references
214 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSBMUG00000004171
Gene Symbol: EPHA2
3 Cross references
124 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSBMUG00000015695
Gene Symbol: EPHA3
3 Cross references
216 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSBMUG00000018474
Gene Symbol: EPHB4
3 Cross references
168 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSBMUG00000003299
Gene Symbol: FAU
2 Cross references
257 Possible Orthologues:

Fkbp Prolyl Isomerase 1a

Ensembl ID : ENSBMUG00000016263
Gene Symbol: FKBP1A
2 Cross references
168 Possible Orthologues:

Fxyd Domain Containing Ion Transport Regulator 2

Ensembl ID : ENSBMUG00000012640
Gene Symbol: FXYD2
2 Cross references
71 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSBMUG00000016879
Gene Symbol: FYN
3 Cross references
264 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSBMUG00000013904
Gene Symbol: GPR119
3 Cross references
176 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSBMUG00000020785
Gene Symbol: GPR84
3 Cross references
122 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSBMUG00000014728
Gene Symbol: HCK
3 Cross references
206 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).